In the Effexor XR case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Wyeth’s (now Pfizer’s) branded antidepressant drug Effexor XR (extended-release venlafaxine hydrochloride capsules). The class also includes direct purchasers of generic versions of Effexor XR from Teva, Wyeth’s co-defendant and alleged co-conspirator. The case alleges that Wyeth hatched an unlawful anticompetitive scheme to delay generic Effexor XR competition, that included fraudulently procuring patents, filing numerous sham patent lawsuits, and then entering into a non-compete agreement with Teva, the generic with the first-filed ANDA, to delay generic competition in exchange for Wyeth’s promise not to launch an authorized generic version of Effexor XR. Violations of §§ 1 and 2 of the Sherman Act are charged. Faruqi & Faruqi, LLP was appointed by the court to the executive committee of this case.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 12/14/2011
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Documents
Second-Amended-Consolidated-Class-Complaint-[ECF-287].pdf
Declaration-of-Peter-S-Pearlman-ISO-Preliminary-Approval-[ECF-729-1].pdf
DPPs-Motion-for-Preliminary-Approval-[ECF-729].pdf
Memo-ISO-DPPs-Motion-for-Preliminary-Approval-[ECF-729-6].pdf
Settlement-Agreement-[ECF-729-2].pdf
Proposed-Plan-of-Allocation-[ECF-729-3].pdf
Declaration-of-Jeffrey-J-Leitzinger-Ph.D-[ECF-729-4].pdf
Declaration-of-William-W-Wickersham-of-RG2-[ECF-729-5].pdf
Order-Granting-DPPs-Motion-for-Preliminary-Approval-[ECF-732].pdf
Effexor-preliminary-approval-order-[4-25-23].pdf
D740-Motion-for-Attorneys-Fees.pdf
D740-1-Effexor-Mem-ISO-Mot-for-Attorneys-Fees.pdf
D740-2-Pearlman-Declaration-with-Exhs.pdf
D740-13-CPA-Signed-Declaration.pdf
D744-Effexor-Motion-for-FA.pdf
D744-1-Effexor-MOL-ISO-Final-Approval.pdf
D744-2-Effexor-Pearlman-Decl-re-FA.pdf